SCHEMBL2068758

SCHEMBL2068758

CCNC(=O)c1ccn[c]c1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHIA Q9BZP6 1/20 0.38
LMNA P02545 1/20 0.37
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
BRD4 O60885 2/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CA1 P00915 1/20 0.35
GAA P10253 1/20 0.35
CA9 Q16790 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
ACVR1 Q04771 1/20 0.34
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067727 0.81 GAA (0.38) ADRA1DADRA1AADRA1BALDH1A1BRD4
SCHEMBL2069207 0.81 SMN1; SMN2 (0.50) LMNAALDH1A1HPGDKMT2AL3MBTL1
SCHEMBL3514318 0.79 CHIA (0.37) CHIALMNAADRA1DADRA1AADRA1B
SCHEMBL2068759 0.77 CA9 (0.35) CHIALMNAALDH1A1HPGDL3MBTL1
SCHEMBL2067871 0.77 ALOX5 (0.46) ADRA1DADRA1AADRA1BALDH1A1KDM4E
SCHEMBL3513476 0.73 ALOX5 (0.36) ALDH1A1HPGDKDM4EGAA
SCHEMBL4673791 0.72 KDM4E (0.58) CHIAALDH1A1HPGDKMT2AL3MBTL1
SCHEMBL3514319 0.70 CA9 (0.34) CHIALMNAADRA1DADRA1AADRA1B
SCHEMBL14917464 0.69 KDM4E (0.46) CHIAALDH1A1HPGDKMT2AL3MBTL1
SCHEMBL13973141 0.69 PRKCI (0.58) CHIAADRA1DADRA1AADRA1BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 CHIA 1086/4885LMNA 860/4885ADRA1D 869/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 CHIA 1086/4885LMNA 860/4885ADRA1D 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.